Protalix BioTherapeutics
PLX
31 hedge funds and large institutions have $27.1M invested in Protalix BioTherapeutics in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 9 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0.29% less ownership
Funds ownership: 2.96% → 2.67% (-0.29%)
9% less funds holding
Funds holding: 34 → 31 (-3)
17% less capital invested
Capital invested by funds: $32.9M → $27.1M (-$5.72M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
51% less call options, than puts
Call options by funds: $43K | Put options by funds: $87K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$6.1M |
| 2 |
BC
Broadfin Capital
New York
|
+$3.39M |
| 3 |
Barclays
London,
United Kingdom
|
+$725K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$311K |
| 5 |
SIM
Spark Investment Management
New York
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.67M |
| 2 |
VAM
Visium Asset Management
New York
|
-$2.95M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.41M |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$1.22M |
| 5 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$730K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EDRH
26
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $4K | – | – | – |
|
27
Bank of America
Charlotte,
North Carolina
| $3K | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| $1K | -$2.94K | -289 | -78% |
|
29
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
30
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | – | – | – |
|
|
31
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$7.67M | -650,362 | Closed |
|
|
VAM
32
Visium Asset Management
New York
| – | -$2.95M | -250,000 | Closed |
|
|
DCM
33
DAFNA Capital Management
Los Angeles,
California
| – | -$1.41M | -119,319 | Closed |
|
|
MTWSIF
34
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
| – | -$730K | -61,868 | Closed |
|
35
BNP Paribas Financial Markets
Paris,
France
| – | -$72.9K | -6,177 | Closed |
|
|
OC
36
Oppenheimer & Co
New York
| – | -$18K | -1,500 | Closed |
|
37
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$12.8K | -1,260 | Closed |
|
|
JFA
38
JNBA Financial Advisors
Bloomington,
Minnesota
| – | -$2K | -200 | Closed |
|
PLX Hedge Fund Activity: Q4 2015 in Review
31 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2015, worth a combined $27.1M — down 17% from $32.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PLX and 6 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 11 added.
The largest buyer was Camber Capital Management, adding an estimated $6.1M. The largest seller was Federated Hermes, exiting entirely with an estimated $7.67M sold.
- 31 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2015, down from 34 in Q3 2015.
- Funds reported $27.1M of Protalix BioTherapeutics stock for Q4 2015, down 17% quarter-over-quarter.
- 6 funds opened new Protalix BioTherapeutics positions in Q4 2015 and 9 closed out, a net change of -3 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2015 was Camber Capital Management, an estimated $6.1M added.
- The largest Protalix BioTherapeutics seller in Q4 2015 was Federated Hermes, an estimated $7.67M sold.
Based on aggregated 13F filings for Q4 2015.